Orexo and Sobi agree to advance feasibility study with AmorphOX Feb 12, 2024 02:09AM
Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC Feb 6, 2024 02:09AM
Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose Nov 28, 2023 02:29AM
Orexo announces changes in the company´s Board of Directors Oct 27, 2023 02:40AM
Orexo´s Nomination Committee for the Annual General Meeting 2024 Oct 26, 2023 11:10AM
View Older Stories

Oct 26, 2023 10:18AM Report from Orexo´s extraordinary general meeting
Sep 5, 2023 08:08AM Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023
Jul 24, 2023 02:24AM Orexo's patent win for ZUBSOLV® appealed
Jul 1, 2023 07:54AM Orexo wins patent litigation for ZUBSOLV® in the US
Apr 18, 2023 01:59PM Report from Orexo AB's annual general meeting
Apr 3, 2023 02:51AM Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124
Mar 28, 2023 09:23AM Orexo publishes the Annual and Sustainability Report for 2022
Mar 15, 2023 02:04PM Orexo postpones publication of the Annual Report
Feb 3, 2023 02:45AM Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Jan 9, 2023 02:10AM Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies
Dec 14, 2022 09:29AM Orexo to Webcast Live at VirtualInvestorConferences.com December 15th  
Oct 28, 2022 07:00AM Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Oct 28, 2022 02:21AM Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Oct 26, 2022 02:49AM Orexo appoints Edward Kim, M.D., as new Chief Medical Officer
Oct 17, 2022 09:33AM Orexo´s Nomination Committee for the Annual General Meeting 2023
Sep 7, 2022 10:50AM Orexo's partner Trinity Health today announces the availability of vorvida® and deprexis® to patients
Sep 1, 2022 02:49AM First patent issued in Europe for Orexo's adrenaline product OX640
Aug 31, 2022 05:52AM Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference
Jul 13, 2022 02:18AM Orexo's digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule
Jul 5, 2022 02:43AM Orexo's nasal adrenaline rescue medication OX640 enters clinical development
Apr 27, 2022 02:22AM Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis
Apr 21, 2022 12:13PM Report from Orexo AB's annual general meeting
Mar 31, 2022 02:28AM Orexo publishes 2021 Annual Report
Mar 11, 2022 02:17AM Orexo appoints Fredrik Järrsten as new CFO
Feb 24, 2022 02:27AM Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List
Nov 26, 2021 02:27AM Orexo provides information about its new proprietary drug delivery platform - amorphOXTM
Nov 16, 2021 02:21AM Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124
Nov 1, 2021 03:33AM Orexo´s Nomination Committee for the Annual General Meeting 2022
Oct 18, 2021 11:07AM Digital Therapeutic MODIA™ Designed to Improve Medication-Assisted Treatment Experience for Opioid Use Disorder
Oct 18, 2021 02:12AM MODIA™ paper published in the Journal of Medical Internet Research Mental Health
Jul 16, 2021 02:47AM Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Jul 12, 2021 08:15AM Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo
Jul 12, 2021 02:33AM Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®
Jul 1, 2021 02:21AM Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Jun 2, 2021 02:28AM Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents
Feb 10, 2021 02:50AM Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management
Feb 5, 2021 10:45AM Orexo calls for redemption of its outstanding bonds and obtains temporary waiver
Feb 4, 2021 12:10PM Orexo has successfully issued senior unsecured callable floating rate bonds
Feb 1, 2021 02:15AM Orexo contemplates issue of senior unsecured callable floating rate bonds
Jan 29, 2021 11:06AM Orexo expects FDA filing of OX124 mid 2022
Jan 27, 2021 02:17AM Orexo strengthens IP rights for overdose rescue drug OX124
Dec 30, 2020 02:09AM Orexo announces new US patent for ZUBSOLV®
Dec 7, 2020 02:14AM Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV® in Europe
Nov 16, 2020 08:39AM Accenture, Orexo Team to Offer Digital Therapeutics through INTIENT™ Platform
Nov 4, 2020 05:23AM Correction notice of press release - Q3 2020 Interim Report - ZUBSOLV® guiding 2020
Oct 15, 2020 05:23PM Orexo and Lyfebulb Announce the Winner of the 2020 Innovation Challenge in Substance Use Disorders
Oct 13, 2020 11:48AM Orexo´s Nomination Committee for the Annual General Meeting 2021
Sep 25, 2020 08:20AM Invitation - Orexo Digital Therapeutics business update October 1
Sep 14, 2020 08:02AM Orexo commences patent infringement litigation against Sun Pharmaceutical
Sep 9, 2020 11:14AM Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options
View Older Stories